Raneem H. Pallotta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raneem H. Pallotta has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Jason M Pogue
Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan
3 shared publications- Samuel L. Aitken
Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan
2 shared publications - Alexander Shaffer
Cleveland Clinic Foundation: Cleveland Clinic
1 shared publication Emily S. Spivak
University of Utah School of Medicine
1 shared publication- Gregory A. Eschenauer
Department of Pharmacy, Michigan Medicine , Ann Arbor, MI
1 shared publication Hannah Imlay
University of Utah School of Medicine
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
The piperacillin-tazobactam is behaving like a prognostic factor, but that does not negate the pharmacodynamic hypothesis
- 16 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessThe piperacillin-tazobactam is behaving like a prognostic factor, but that does not negate the pharmacodynamic hypothesis
- Open Access
- 2 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Cefepime versus piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa pneumonia
Background: Both piperacillin-tazobactam and cefepime are widely used for the treatment of pneumonia caused by Pseudomonas aeruginosa. Despite this, no studies have directly compared these agents for this purpose. Methods: We performed a single-center retrospective cohort study of patients with pneumonia caused by P. aeruginosa treated with piperacillin-tazobactam or cefepime. The co-primary outcomes were 30-day mortality and a 30-day desirability of outcome ranking (DOOR) incorporating clinical failure, resistance, acute kidney injury (AKI), and recurrence. Overlap-weighted (OW) analyses were used to account for confounding. Results: A total of 204 patients (piperacillin-tazobactam, n = 117; cefepime, n = 87) were included. Baseline characteristics were comparable between groups after OW. All-cause mortality occurred more frequently in patients who received piperacillin-tazobactam (23.1%) compared with those receiving cefepime (11.5%; p = 0.04, OW odds ratio 2.38, 95% CI 1.05–5.42). Conversely, no significant difference in the DOOR endpoint associated with receipt of piperacillin-tazobactam (46%, 95% CI 39% – 53%) was demonstrated. Rates of resistance development (12.0% vs 5.7%, p = 0.15; OW subhazard ratio 2.25, 95% CI 0.79–6.43), and clinical success (65% vs 70%; OW odds ratio 0.81, 95% CI 0.43–1.51) were similar amongst patients receiving piperacillin-tazobactam and cefepime, respectively. AKI incidence on study drug was likewise similar (7.0% vs 7.2%). Conclusion: In this comparative study of cefepime and piperacillin-tazobactam for P. aeruginosa pneumonia, increased risk of mortality was seen with piperacillin-tazobactam. No differences were seen in other key outcomes, although sample size limits interpretation. This finding warrants further investigation in larger studies.
- 2 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessCefepime versus piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa pneumonia
Background: Both piperacillin-tazobactam and cefepime are widely used for the treatment of pneumonia caused by Pseudomonas aeruginosa. Despite this, no studies have directly compared these agents for this purpose. Methods: We performed a single-center retrospective cohort study of patients with pneumonia caused by P. aeruginosa treated with piperacillin-tazobactam or cefepime. The co-primary outcomes were 30-day mortality and a 30-day desirability of outcome ranking (DOOR) incorporating clinical failure, resistance, acute kidney injury (AKI), and recurrence. Overlap-weighted (OW) analyses were used to account for confounding. Results: A total of 204 patients (piperacillin-tazobactam, n = 117; cefepime, n = 87) were included. Baseline characteristics were comparable between groups after OW. All-cause mortality occurred more frequently in patients who received piperacillin-tazobactam (23.1%) compared with those receiving cefepime (11.5%; p = 0.04, OW odds ratio 2.38, 95% CI 1.05–5.42). Conversely, no significant difference in the DOOR endpoint associated with receipt of piperacillin-tazobactam (46%, 95% CI 39% – 53%) was demonstrated. Rates of resistance development (12.0% vs 5.7%, p = 0.15; OW subhazard ratio 2.25, 95% CI 0.79–6.43), and clinical success (65% vs 70%; OW odds ratio 0.81, 95% CI 0.43–1.51) were similar amongst patients receiving piperacillin-tazobactam and cefepime, respectively. AKI incidence on study drug was likewise similar (7.0% vs 7.2%). Conclusion: In this comparative study of cefepime and piperacillin-tazobactam for P. aeruginosa pneumonia, increased risk of mortality was seen with piperacillin-tazobactam. No differences were seen in other key outcomes, although sample size limits interpretation. This finding warrants further investigation in larger studies.
- Open Access
- 14 July 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Charting new territory: outpatient stewardship in immunocompromised patients (first of a two-part series)
Antimicrobial stewardship (AS) among immunocompromised (IC) patients is a growing field. Since most antibiotic use occurs in the outpatient setting, antimicrobial use among IC outpatients represents an opportune area for stewardship. This two-part review explores the current state of outpatient AS in immunocompromised hosts, highlighting potential stewardship interventions and published strategies, as well as barriers in this vulnerable population. In this first section, we will highlight stewardship interventions in clinical syndromes relevant to both immunocompetent and IC hosts, including spectrum and duration of antibiotics for common bacterial infections, antibiotic allergy management, immunizations, periprocedural antimicrobial management, and multiplex polymerase chain reaction diagnostics.
- 14 July 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Open AccessCharting new territory: outpatient stewardship in immunocompromised patients (first of a two-part series)
Antimicrobial stewardship (AS) among immunocompromised (IC) patients is a growing field. Since most antibiotic use occurs in the outpatient setting, antimicrobial use among IC outpatients represents an opportune area for stewardship. This two-part review explores the current state of outpatient AS in immunocompromised hosts, highlighting potential stewardship interventions and published strategies, as well as barriers in this vulnerable population. In this first section, we will highlight stewardship interventions in clinical syndromes relevant to both immunocompetent and IC hosts, including spectrum and duration of antibiotics for common bacterial infections, antibiotic allergy management, immunizations, periprocedural antimicrobial management, and multiplex polymerase chain reaction diagnostics.
- Open Access
- 3 July 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e197
Provider perceptions of an antimicrobial stewardship program in immunocompromised patients at a cancer center
Although provider opposition has been identified as a barrier to initiating antimicrobial stewardship programs (ASPs) among immunocompromised (IC) patients, little is known about perceptions of IC ASPs postimplementation. We assessed provider perceptions of our cancer hospital-focused ASP. Respondents found the ASP to be acceptable and value-added.
- 3 July 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e197
Open AccessProvider perceptions of an antimicrobial stewardship program in immunocompromised patients at a cancer center
Although provider opposition has been identified as a barrier to initiating antimicrobial stewardship programs (ASPs) among immunocompromised (IC) patients, little is known about perceptions of IC ASPs postimplementation. We assessed provider perceptions of our cancer hospital-focused ASP. Respondents found the ASP to be acceptable and value-added.